Atlas Trials

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Clinical trial NCT01068587 · COMPLETED

Trial details

NCT number
NCT01068587
Sponsor
NCIC Clinical Trials Group
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Lung Cancer
Start date
2010-01-21
Primary completion
2014-03-21
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.